Dare Bioscience, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-13.4M | $-4.1M | $-30.2M | $-30.9M | $-38.7M | $-27.4M | $-14.3M | $-16.7M |
| Depreciation & Amortization | $1.6M | $42.3K | — | — | — | — | — | — |
| Depreciation | $162.0K | $42.0K | $38.4K | $24.2K | $26.4K | $43.2K | $11.1K | $2.4K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.5M | $2.2M | $2.5M | $2.2M | $1.6M | $742.0K | $462.2K | $139.3K |
| Net Cash from Operating Activities | $-9.9M | $5.5M | $-38.9M | $-18.1M | $-28.8M | $-25.2M | $-13.3M | $-10.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $385.3K | $573.0K | $629.4K | $63.1K | $14.5K | $17.6K | $0 | $11.8K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-385.3K | $-573.0K | $-629.4K | $-63.1K | $-14.5K | $-17.6K | $6.1M | $-518.8K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $19.3M | $354.5K | $15.6M | $1.3M | $75.8M | $25.1M | $5.2M | $10.1M |
| Net Change in Cash | $9.0M | $5.2M | $-23.9M | $-17.0M | $47.0M | $-110.6K | $-2.0M | $-754.0K |
| Free Cash Flow | $-10.3M | $4.9M | $-39.5M | $-18.2M | $-28.8M | $-25.3M | $-13.3M | $-10.3M |